مرزهای کشف داروهای ضدسرطان جلد: ۸

Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest and the most important advances in anti-cancer drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The book series should prove to be of interest to all pharmaceutical scientists involved in research in anti-cancer drug design and discovery. Each volume is devoted to the major advances in anti-cancer drug design and discovery. The book series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field. The eighth volume of the series features chapters covering the following topics: - T cells in gastrointestinal cancers - The pharmacology of adjudin – a male contraceptive with anti-cancer properties - Manipulating the tumor microenvironment - Treatment of hepatocellular carcinoma - Gold-based compounds as potential anti-cancer drug candidates - Oral nanostructure drug delivery for anti-cancer treatment Content: Cover Title Biblography End User License Agreement Contents Preface List of Contributors Recent Advances and New Insights for the Therapeutic Intervention of Cancer Nhi Nguyen1, Stina George Fernandes2, Ekta Khattar2 and Yinghui Li1,* TARGETING DNA DAMAGE RESPONSE (DDR) IN CANCER DNA Damage Response Pathways Base Excision Repair (BER) DNA Mismatch Repair (MMR) Nucleotide Excision Repair (NER) DNA Double Strand Break Repair DDR Associated Cell Signalling Pathways DDR as an Anticancer Drug Target DDR Inhibitors in Clinical Development Combining DDR Inhibitors with DNA Damaging Radiotherapy and ChemotherapyFuture Prospects of DDR Targeting Agents in Cancer Treatment Synthetic Lethality DDR with Epigenetic Compounds IMMUNOTHERAPY Common Immunotherapeutic Approaches Cytokine Therapy Antibody Immunotherapy Therapeutic Cancer Vaccination Therapy Oncolytic Viruses Therapy Adoptive Cell Transfer Therapy The Basis Behind CAR-T and CD19 CAR-T Therapy Advantages of CD19 CAR-T Cell Therapy Common Side Effects and Considerations of CD19 CAR-T Cell Therapy Clinical Application and Drug Development of CD19 CAR-T Cell TherapyTisagenlecleucel Axicabtagene Ciloleucel Future Perspective of CAR and CD19 CAR-T Cell Therapy CAR Construct Delivery System Novel CAR-T Models CONCLUSION CONSENT FOR PUBLICATION CONFLICT OF INTEREST ACKNOWLEDGEMENTS REFERENCE Dabrafenib in Melanoma Meredith McKean and Rodabe N. Amaria* INTRODUCTION Mechanism of Action Pharmacokinetics and Pharmacodynamics Clinical Evaluations Phase I and Phase II Studies Phase III Studies Dabrafenib for CNS Metastases Dabrafenib/Trametinib Combination Therapy Adjuvant Combination Targeted TherapyNeoadjuvant Combination Targeted Therapy Dabrafenib/Trametinib for CNS Metastases Safety Immunotherapy and Targeted Therapy BRAF V600 Mutation in Other Malignancies CONCLUSIONS CONSENT FOR PUBLICATION CONFLICT OF INTEREST ACKNOWLEDGEMENTS REFERENCES Targeting Autophagy in Cancer Therapy Maria Ines Vaccaro1,* and Claudio Daniel Gonzalez2 AUTOPHAGY IS AN EVOLUTIONARY HIGHLY PRESERVED PHYSIOLOGICAL PROCESS Signaling Pathway for Autophagy Autophagic Process Functions of Autophagy ALTERATIONS IN AUTOPHAGY ARE ASSOCIATED WITH TRANSITION FROM NORMAL TO NEOPLASTIC CELLS, AS WELL AS WITH CANCER CELL SURVIVAL AND RESISTANCE TO CHEMOTHERAPYAutophagy in Normal to Neoplastic Cells Autophagy in Cancer Cell Survival Autophagy in Resistance to Chemotherapy ACTIVATION AND INHIBITION OF AUTOPHAGY IN CHEMOTHERAPY OF CANCER Cancer Cell Response After Autophagy Enhancement Cancer Cell Response After Inhibition of Autophagy AUTOPHAGY IN IMMUNOTHERAPY FOR CANCER CONCLUSIONS AND PERSPECTIVES CONSENT FOR PUBLICATION CONFLICT OF INTEREST ACKNOWLEDGEMENTS REFERENCES Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest advances in anti-cancer drug design and discovery. In each volume, eminent scientists contribute reviews relevant to all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The book series should prove to be of interest to all pharmaceutical scientists involved in research in anti-cancer drug design and discovery. The book series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field. The ninth volume of the series features chapters covering the following topics: - New research on the therapeutic intervention of cancer and cancer drug delivery - Dabrafenib usage in melanoma therapy - Targeting autophagy in cancer therapy - Pro-apoptotic and anti-telomerase activity of naturally occurring compounds - CDK inhibitors - Oral nanostructure drug delivery for anti-cancer treatment

Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest advances in anti-cancer drug design and discovery. In each volume, eminent scientists contribute reviews relevant to all areas of rational drug design and drug disc